Corient Private Wealth LLC Sells 5,352 Shares of Solventum Co. (NYSE:SOLV)

Corient Private Wealth LLC lowered its stake in shares of Solventum Co. (NYSE:SOLV) by 9.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 54,269 shares of the company’s stock after selling 5,352 shares during the quarter. Corient Private Wealth LLC’s holdings in Solventum were worth $3,585,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Choate Investment Advisors grew its position in Solventum by 19.1% during the fourth quarter. Choate Investment Advisors now owns 3,707 shares of the company’s stock valued at $245,000 after buying an additional 594 shares during the period. Natixis Advisors LLC grew its position in Solventum by 14.3% during the fourth quarter. Natixis Advisors LLC now owns 54,406 shares of the company’s stock valued at $3,594,000 after buying an additional 6,790 shares during the period. Diamond Hill Capital Management Inc. bought a new position in Solventum during the fourth quarter valued at about $15,913,000. Madison Investment Advisors LLC bought a new position in Solventum during the fourth quarter valued at about $322,000. Finally, Thompson Siegel & Walmsley LLC grew its position in Solventum by 1.1% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 111,937 shares of the company’s stock valued at $7,395,000 after buying an additional 1,218 shares during the period.

Analyst Ratings Changes

A number of equities analysts have weighed in on SOLV shares. Piper Sandler increased their target price on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. The Goldman Sachs Group increased their target price on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research report on Monday, March 3rd. Mizuho increased their target price on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, March 3rd. Bank of America increased their target price on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 26th. Finally, Wells Fargo & Company increased their target price on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $79.86.

Solventum Trading Down 1.3 %

Shares of Solventum stock opened at $74.00 on Friday. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $85.92. The company has a market cap of $12.80 billion and a price-to-earnings ratio of 26.91. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The company’s 50-day moving average price is $75.17 and its 200-day moving average price is $71.56.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.